Tamnorzatinib

N/A

Report date: 2025/07/01 15:17:10
NME

Base Information

Drug NameTamnorzatinib
Drug Alias NameONO-7475
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTyrosine-protein kinase Mer inhibitors
TargetsAXL receptor tyrosine kinaseTyrosine-protein kinase Mer
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOno Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Inactive IndicationsMyelodysplastic SyndromesLeukemia

Other Information

ATC CodeN/A
Related LinksN/A